[{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Juvenile Diabetes Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK||Glucokinase (GCK)","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Juvenile Diabetes Research Foundation","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Juvenile Diabetes Research Foundation"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK||Glucokinase (GCK)","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"G42 Investments","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ G42 Investments","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ G42 Investments"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Reneo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Reneo Pharmaceuticals"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ CinRx Pharma","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ CinRx Pharma"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Samsara BioCapital"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Cadisegliatin","moa":"GCK","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Samsara BioCapital"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TTP273","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GK1-399","moa":"Glucokinase (GCK)","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HPP737","moa":"PDE4","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HPP737","moa":"PDE4","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"TTP054","moa":"PPAR-alpha","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"TTP4000","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by vTv Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
